Effect of Local Administration of Lymphokine-activated Killer Cells and Interleukin-2 on Malignant Brain Tumor Patients

Yukihiro IBAYASHI; Toshiaki YAMAKI; Takahisa KAWAHARA; Masahiko DAIBO; Tsukasa KUBOTA; Teiji UEDE; Sumiyoshi TANABE; Kazuo HASHI

doi:10.2176/nmc.33.448

Yukihiro IBAYASHI, Toshiaki YAMAKI, Takahisa KAWAHARA, Masahiko DAIBO, Tsukasa KUBOTA, Teiji UEDE, Sumiyoshi TANABE, Kazuo HASHI

著者情報

キーワード: lymphokine-activated killer cell, interleukin-2, malignant tumor, immunotherapy, glioma

ジャーナルフリー

1993 年 33 巻 7 号 p. 448-457

DOI https://doi.org/10.2176/nmc.33.448

詳細

抄録

Nine patients with malignant brain tumors were treated with intratumoral infusion of lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2). LAK cells were generated from macrophagedepleted peripheral blood lymphocytes by culturing with IL-2 for 4 days. The resulting LAK cells showed strong cytotoxic activity against tumor target cells. Three patients received sufficient LAK cells (≥ 5.76 × 10⁸) to show partial tumor response by computed tomography and clinical signs. No severe neurological side effects occurred in any patient. Intratumoral administration of LAK cells and IL-2 can be effective in patients with malignant brain tumors.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）